Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients

Inclusion Criteria

Patients with new diagnoses of non-M3 AML or high-risk MDS, myeloproliferative neoplasms (MPN), or myelofibrosis (MF) (showing 10% or more blasts in bone marrow) who:

Present for an AML-like treatment that could plausibly produce a complete remission (CR); for example intensive induction chemotherapy, low dose single agent chemotherapy, hypomethylation agent, or a similar therapy
Possibility to retrieve follow-up records from the collaborating institution or treating primary care physician
Patients with primary refractory or first relapse presenting for salvage chemotherapy will be allowed
Patients of 18 years of age or older, and are being treated by the adult AML service.
Able to speak and read English.
Willing and able to provide informed consent.

Exclusion Criteria

Patients of ≤17 years of age or who are 18 or older and receive treatment under the pediatric AML service.
Patients older than 80 years
Patients with <6 months projected survival due to active second malignancy or other medical problem.